Navigation Links
Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue
Date:11/3/2010

ns

142376186310Dilutive effect of convertible senior notes (4)5,8015,801-5,801Non-GAAP diluted shares (3)68,65066,42562,74864,312Non-GAAP net income per share (3)$
.88$
.37$
.91$
.78Non-GAAP net income per share - diluted (3) $
.84$
.35$
.90$
.73(3)
This press release includes the following non-GAAP financial measures: non-GAAP net income, non-GAAP net income – diluted, non-GAAP net income per share, and non-GAAP net income per share – diluted. The foregoing table reconciles these non-GAAP measures to the most comparable financial measures calculated in accordance with GAAP.Onyx management uses these non-GAAP financial measures to monitor and evaluate our operating results and trends on an on-going basis and internally for operating, budgeting and financial planning purposes. Onyx management believes the non-GAAP information is useful for investors by offering them the ability to better identify trends in our business and better understand how management evaluates the business. These non-GAAP measures have limitations, however, because they do not include all items of income and expense that affect Onyx. These non-GAAP financial measures that management uses are not prepared in accordance with, and should not be considered in isolation of, or an as alternative to, measurements required by GAAP.These non-GAAP financial measures exclude the following items from GAAP net income (loss) and diluted per share amounts:Contingent consideration expense
: The effects of contingent consideration expense are excluded due to the nature of this charge, which is related to the change in fair value of the liability for contingent consideration in connection with the acquisition of Proteolix; such exclusion facilitates comparisons of Onyx's operating results to peer companies.Employee stock-based compensation
: The effects of employee stock-based compensation are excluded because of varying available valuation m
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Vanda Pharmaceuticals Reports Third Quarter 2010 Results
2. OncoMed Pharmaceuticals Awarded Five Therapeutic Discovery Project Grants Totaling $1.2 Million
3. Transcept Pharmaceuticals to Report Third Quarter 2010 Results and Host Conference Call on November 11, 2010
4. Anthera Pharmaceuticals Reports 2010 Third Quarter Financial Results and Operational Update
5. ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results
6. DUSA Pharmaceuticals, Inc.® to Host Third Quarter 2010 Corporate Highlights and Financial Results Conference Call
7. Access Pharmaceuticals Awarded $1.5 Million in Section 48D Grants
8. Anadys Pharmaceuticals to Report Third Quarter 2010 Financial Results
9. Alder Biopharmaceuticals Appoints Bruce Montgomery to Board of Directors
10. Alexza Pharmaceuticals to Announce 2010 Third Quarter Financial Results on November 9, 2010
11. AVANIR Pharmaceuticals Invites Investors to Conference Call Regarding FDA Approval of NUEDEXTA™ on Monday November 1, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... SHANGHAI, March 5, 2015 WuXi PharmaTech (Cayman) ... R&D capability and technology platform company serving the pharmaceutical, ... and the United States, today announced its financial results ... Fourth-Quarter 2014 Highlights , Net Revenues ... , Laboratory Services Net Revenues Grew 17.7% Year Over ...
(Date:3/5/2015)... Germany , March 5, 2015 ... and CureVac today announced that the foundation has ... million) in CureVac, a leading clinical-stage biopharmaceutical company ... the agreement, the foundation will also provide separate ... based on CureVac,s proprietary messenger RNA (mRNA) platform. ...
(Date:3/5/2015)... , March 5, 2015 CANTEL MEDICAL CORP. (NYSE: ... second quarter ended January 31, 2015 on Thursday, March 12 ... discuss the results at 11:00 AM ET. ... 5 to 10 minutes before the beginning of the call. ... the call will be available from Thursday, March 12, 2015 ...
Breaking Medicine Technology:WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 2WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 4WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 6WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 7WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 8WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 9WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 10WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 11WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 12WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 13WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 14WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 15WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 16WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 17WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 18WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 19WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 20WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 21WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 22The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 2The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 3The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 4Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Second Quarter Ended January 31, 2015 2
(Date:3/6/2015)... 06, 2015 At Natural Products ... today the launch of its powerful, location-aware iOS ... and sustainable products at any retailer that carries ... at Expo West Booth 6054. , Makeena’s ... Kosher, non-GMO, organic, Paleo, and vegan, among many ...
(Date:3/6/2015)... Since Medicare began paying for chronic care ... an overwhelming demand from providers for straightforward guidance on ... The Centers for Medicare & Medicaid Services (CMS) ... updated white paper—“ Providing and Billing Medicare for Chronic ... yet practical “how to” manual for providers looking to ...
(Date:3/6/2015)... 06, 2015 Jvion, the Atlanta-based ... of a Clostridium Difficile (C Diff) predictive use ... Diff use case is the latest in a ... acquired infections, chronic conditions, and individual illnesses. Using ... Diff solution flags at risk individuals to help ...
(Date:3/6/2015)... Utilizing the latest in nutritional science to help ... has enabled Diet Doc to add powerful new ... of fat loss enhancement medications. And now, they are ... to help people throughout the country begin losing dangerous ... appealing to new clients because they can receive Appetite ...
(Date:3/6/2015)... March 06, 2015 The Gluten-Free ... Celiac Association, is pleased to announce that Dufflet ... Rosenberg, has expanded their product line of gluten-free ... as scrumptious and as satisfying as any of ... scratch, and never contains hydrogenated fats or oils, ...
Breaking Medicine News(10 mins):Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 3Health News:Updated PYA White Paper Meets Demand for Guidance on Providing and Billing Medicare for Chronic Care Management 2Health News:Jvion Predicts Patients at Risk of C Difficile Infection to Reduce Risk and Save Lives 2Health News:Diet Doc Announces Never Before Offered Discounts, Promotions and Savings for New and Existing Clients 2Health News:Diet Doc Announces Never Before Offered Discounts, Promotions and Savings for New and Existing Clients 3Health News:Diet Doc Announces Never Before Offered Discounts, Promotions and Savings for New and Existing Clients 4Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 2Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 3Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 4
... RESEDA, Calif., June 16 The famed nonprofit Los ... prevention and,fitness program designed to address one of the ... by the Jewish Community Foundation,the largest manager of charitable ... new fall prevention and fitness program becomes part of ...
... RELEASE, 16 June 2008] A unique new study from the ... of families and the public have little impact on if ... or the opposite sex. Instead, hereditary factors and the individual,s ... sexual partners. , The study is the largest in the ...
... recognize partners, innovative use of Microsoft technology to ... customer expectations and solve business ... partners,that delivered exemplary solutions to customers, Microsoft Corp. ... Microsoft Partner of the,Year Awards. The awards honor ...
... 16 BME (BioMedical Enterprises,Inc.), a privately held ... implant technology, today announced the launch of the ... fixation of,bone., The BOSS is an orthopaedic ... adhesion. Like the BME OSStaple(TM) product line, the ...
... Comprehensive Cancer Center, has been appointed by President Bush to the ... appointees named to the board on June 12, 2008. , The ... National Cancer Institute (NCI). The role of the board is ... Services and the director of the NCI on issues that ...
... provider based at The University of Queensland, and Q-Pharm, ... have formed a strategic alliance. , The alliance ... clients in the biotechnology and pharmaceutical industries. , ... the two businesses, which are both commercialisation enterprises of ...
Cached Medicine News:Health News:Los Angeles Jewish Home Institutes New Fall Prevention Program With Jewish Community Foundation Grant 2Health News:Los Angeles Jewish Home Institutes New Fall Prevention Program With Jewish Community Foundation Grant 3Health News:Microsoft Announces 2008 Partner of the Year Awards Finalists and Winners 2Health News:Microsoft Announces 2008 Partner of the Year Awards Finalists and Winners 3Health News:Microsoft Announces 2008 Partner of the Year Awards Finalists and Winners 4Health News:Microsoft Announces 2008 Partner of the Year Awards Finalists and Winners 5Health News:Microsoft Announces 2008 Partner of the Year Awards Finalists and Winners 6Health News:Microsoft Announces 2008 Partner of the Year Awards Finalists and Winners 7Health News:BME (BioMedical Enterprises, Inc.) Announces U.S. Launch of the Barbed OSStaple(TM) (BOSS) Nitinol Implant 2Health News:TetraQ and Q-Pharm form strategic alliance 2Health News:TetraQ and Q-Pharm form strategic alliance 3
Trilogy Pacemakers incorporates the clinically proven Omniscence™ accelerometer sensor with it's automatic alogorithms. The Trilogy family of pacemakers feature an array of products for bradyar...
... The Identity pacemaker family, which ... pacemaker, provides clinicians with the ... including the revolutionary AF Suppression™ ... U.S. commercially approved algorithm designed ...
Innovative new tools for more efficient patient management begin when the pacemaker is implanted. These sophisticated tools are in effect each day, and they help automate follow-up tasks....
The INSIGNIA® pacing systems allow the physician to provide customized adaptive-rate pacing therapy to meet individual patient needs....
Medicine Products: